Study S000173

A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02533453
Acronym: Bydureon
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 110
Start: 2016-01-28
Primary completion: 2016-12-07
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes Mellitus
Interventions: BIOLOGICAL:Bydureon
Results posted: TRUE

Registered primary outcomes

Percentage of Participants With Adverse Events(AEs) and Serious Adverse Event(SAEs) [baseline and 12/24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.